Myocardial Infarction Treatment Market - Global Industry Analysis

Market Overview     

The global Myocardial Infarction Treatment market accounted for USD 1553 Million in 2020 and is expected to reach USD 2246.10 Million by 2028, growing at a CAGR of around 4.6% between 2021 and 2028.

Growing cases of cardiovascular ailments and sedentary life patterns will impact the expansion of the myocardial infarct treatment market within the years ahead. Besides this, factors like obesity, diabetes, smoking habits, hypertension, low physical activity, and diabetes are anticipated to impact the expansion of the myocardial infarct treatment market within the near future. Escalating drug costs alongside growing expenditure on clinical trials are probably going to hamper the expansion of the myocardial infarct treatment market within the coming years.

Furthermore, rising costs of R& D programs alongside strict legislation governing the treatment can obstruct the business growth within the ensuing years. Nonetheless, mounting adoption of innovative treatment methods across developing nations will boost the industry revenue, thereby normalizing the impact of hindrances on the myocardial infarct treatment market, reports the myocardial infarct treatment market study.

COVID-19 Impact Analysis  

Besides, the COVID-19 outbreak, there's a drastic rise in the demand for healthcare facilities across the world. 2020 has been a dramatic rush of ICU visits and checkups so far, all because of a pandemic that has shaken the entire world. The Novel Coronavirus that caused the COVID-19 disease unleashed a disaster of extraordinary proportions. As healthcare spends for COVID-19 increases exponentially, companies that conduct research, develop potential vaccines, produce test kits, and manufacture or supply medical equipment are likely to benefit the most. The reason is clear - governments across the world will invest in not only damage control, but also in the prevention of any potential resurgence of the pandemic. This also means that companies other than those manufacturing PPE or infrastructure support that is not directly connected to COVID-19 would face disruptions in business.

Growth Factors

Globally, the increasing incidence of arteria coronaria disease and changes in lifestyle, an increasing number of smokers, increasing incidence of obesity, and lack of exercise are the prime growth drivers of the worldwide myocardial infarct Treatment market. Additionally, an increase in the adoption of myocardial infarct Treatment in emerging economies like China, India among others, will create new opportunities for the global myocardial infarct Treatment market. However, the upper cost of research and development, and limited R&D Activities are the key restraints for the global myocardial infarct Treatment market.

Report Scope:  

Segment Analysis Preview  

Based on product type the market is segmented into antiplatelet agents, glycoprotein IIb/IIIa inhibitors, antithrombotic agents, beta-adrenergic blockers, vasodilators, angiotensin-converting enzyme (ace) inhibitors, angiotensin-receptor blockers, analgesics, thrombolytics. Key distribution channels covered under this study include hospitals, hospital pharmacies, drug stores, and online drug stores. 

Based on distribution channels, hospitals and hospital pharmacies both have accounted for the major market share in 2018 due to the increased investments in healthcare infrastructure & the use of advanced technologies. However, online drug stores are expected to witness the fastest growth within the forecast period due to increasing demand from healthcare participants in surgical care such as; healthcare professionals, patients, and insurers. Additionally, increasing demand for patient satisfaction, cost-effective procedures, and efficient practices by healthcare professionals also are expected to spice up the expansion of this market within the forecast period.

Regional Analysis Preview

Regionally, North America has been leading the worldwide myocardial infarct treatment market and is anticipated to continue on the dominant position within the years to return. The rise in the geriatric population base and growing cases of heart ailments is that the main factor behind the dominance of the North American myocardial infarct treatment market. The high number of market players being headquartered in North America is another significant factor that's supporting this regional myocardial infarct treatment market.

Key Market Players & Competitive Landscape

The major players that are comprised in  Myocardial Infarction Treatment market are Bayer, Novartis, Daiichi Sankyo Company Limited, Boehringer Ingelheim GmbH, Sandoz, Astrazeneca, Janssen Biotech, Inc., Merck & Co. Inc., Sanofi, Pfizer Inc. among others.

The global  Myocardial Infarction Treatment Market is segmented as follows:

By Product Type

• Antiplatelet agents
• Glycoprotein IIb/IIIa inhibitors
• Antithrombotic agents
• Beta-adrenergic blockers
• Vasodilators
• Angiotensin-Converting Enzyme (ACE) inhibitors
• Angiotensin-Receptor blockers
• Analgesics
• Thrombolytics

By Distribution Channel

• Hospitals
• Hospital Pharmacies
• Drug Stores
• Online Drug Stores

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

• Chapter No. 1 Introduction
  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. USP & Key Offerings
  • 1.2. Key Benefits for Stakehulders
  • 1.3. Target Audience
  • 1.4. Report Scope
• Chapter No. 2 Executive Summary
  • 2.1. Key Findings
    • 2.1.1. Top Investment Pockets
      • 2.1.1.1. Market Attractiveness Analysis, By Product
      • 2.1.1.2. Market Attractiveness Analysis, By Distribution Channel
      • 2.1.1.3. Market Attractiveness Analysis, By Region
  • 2.2. Market Snapshot
  • 2.3. Global Myocardial Infarction Treatment Market, 2016 – 2028 (USD Million)
  • 2.4. Insights from Primary Respondents
• Chapter No. 3 COVID 19 Impact Analysis
  • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
    • 3.1.1. North America
    • 3.1.2. Europe
    • 3.1.3. Asia Pacific
    • 3.1.4. Latin America
    • 3.1.5. The Middle-East and Africa
  • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
  • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
  • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
  • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
    • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
  • 3.6. Short Term Dynamics
  • 3.7. Long Term Dynamics
• Chapter No. 4 Myocardial Infarction Treatment Market – Product Segment Analysis
  • 4.1. Overview
    • 4.1.1. Market Revenue Share, By Product, 2020 & 2028
  • 4.2. Antiplatelet agents
    • 4.2.1. Market Size and Forecast, By Region (USD Million)
    • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
  • 4.3. GLYCOPROTEIN IIB/IIIA INHIBITORS
    • 4.3.1. Market Size and Forecast, By Region (USD Million)
    • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
  • 4.4. Antithrombotic agents
    • 4.4.1. Market Size and Forecast, By Region (USD Million)
    • 4.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 4.4.3. Key Market Trends, Growth Factors, & Opportunities
  • 4.5. Beta-adrenergic blockers
    • 4.5.1. Market Size and Forecast, By Region (USD Million)
    • 4.5.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 4.5.3. Key Market Trends, Growth Factors, & Opportunities
  • 4.6. Vasodilators
    • 4.6.1. Market Size and Forecast, By Region (USD Million)
    • 4.6.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 4.6.3. Key Market Trends, Growth Factors, & Opportunities
  • 4.7. Angiotensin-Converting Enzyme (ACE) inhibitors
    • 4.7.1. Market Size and Forecast, By Region (USD Million)
    • 4.7.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 4.7.3. Key Market Trends, Growth Factors, & Opportunities
  • 4.8. Angiotensin-Receptor blockers
    • 4.8.1. Market Size and Forecast, By Region (USD Million)
    • 4.8.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 4.8.3. Key Market Trends, Growth Factors, & Opportunities
  • 4.9. Analgesics
    • 4.9.1. Market Size and Forecast, By Region (USD Million)
    • 4.9.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 4.9.3. Key Market Trends, Growth Factors, & Opportunities
  • 4.10. Thrombulytic
    • 4.10.1. Market Size and Forecast, By Region (USD Million)
    • 4.10.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 4.10.3. Key Market Trends, Growth Factors, & Opportunities
• Chapter No. 5 Myocardial Infarction Treatment Market – Distribution Channel Segment Analysis
  • 5.1. Overview
    • 5.1.1. Market Revenue Share, By Distribution Channel, 2020 & 2028
  • 5.2. Hospitals
    • 5.2.1. Market Size and Forecast, By Region (USD Million)
    • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
  • 5.3. Hospital Pharmacies
    • 5.3.1. Market Size and Forecast, By Region (USD Million)
    • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
  • 5.4. Drug Stores
    • 5.4.1. Market Size and Forecast, By Region (USD Million)
    • 5.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 5.4.3. Key Market Trends, Growth Factors, & Opportunities
  • 5.5. Online Drug Stores
    • 5.5.1. Market Size and Forecast, By Region (USD Million)
    • 5.5.2. Comparative Revenue Analysis, By Country, 2020 & 2028
    • 5.5.3. Key Market Trends, Growth Factors, & Opportunities
• Chapter No. 6 Myocardial Infarction Treatment Market – Region Segment Analysis
  • 6.1. Overview
    • 6.1.1. Global Market Revenue Share, By Region, 2020 & 2028
    • 6.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 6.2.2. North America Market Revenue, By Product, 2016 – 2028
    • 6.2.3. North America Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.2.5. U.S.
      • 6.2.5.1. U.S. Market Revenue, By Product, 2016 – 2028
      • 6.2.5.2. U.S. Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.2.6. Canada
      • 6.2.6.1. Canada Market Revenue, By Product, 2016 – 2028
      • 6.2.6.2. Canada Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.2.7. Mexico
      • 6.2.7.1. Mexico Market Revenue, By Product, 2016 – 2028
      • 6.2.7.2. Mexico Market Revenue, By Distribution Channel, 2016 – 2028
  • 6.3. Europe
    • 6.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 6.3.2. Europe Market Revenue, By Product, 2016 – 2028
    • 6.3.3. Europe Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.3.5. Germany
      • 6.3.5.1. Germany Market Revenue, By Product, 2016 – 2028
      • 6.3.5.2. Germany Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.3.6. France
      • 6.3.6.1. France Market Revenue, By Product, 2016 – 2028
      • 6.3.6.2. France Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.3.7. U.K.
      • 6.3.7.1. U.K. Market Revenue, By Product, 2016 – 2028
      • 6.3.7.2. U.K. Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.3.8. Italy
      • 6.3.8.1. Italy Market Revenue, By Product, 2016 – 2028
      • 6.3.8.2. Italy Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.3.9. Spain
      • 6.3.9.1. Spain Market Revenue, By Product, 2016 – 2028
      • 6.3.9.2. Spain Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.3.10. Rest of Europe
      • 6.3.10.1. Rest of Europe Market Revenue, By Product, 2016 – 2028
      • 6.3.10.2. Rest of Europe Market Revenue, By Distribution Channel, 2016 – 2028
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 6.4.2. Asia Pacific Market Revenue, By Product, 2016 – 2028
    • 6.4.3. Asia Pacific Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.4.5. China
      • 6.4.5.1. China Market Revenue, By Product, 2016 – 2028
      • 6.4.5.2. China Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.4.6. Japan
      • 6.4.6.1. Japan Market Revenue, By Product, 2016 – 2028
      • 6.4.6.2. Japan Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.4.7. India
      • 6.4.7.1. India Market Revenue, By Product, 2016 – 2028
      • 6.4.7.2. India Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.4.8. South Korea
      • 6.4.8.1. South Korea Market Revenue, By Product, 2016 – 2028
      • 6.4.8.2. South Korea Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.4.9. South-East Asia
      • 6.4.9.1. South-East Asia Market Revenue, By Product, 2016 – 2028
      • 6.4.9.2. South-East Asia Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.4.10. Rest of Asia Pacific
      • 6.4.10.1. Rest of Asia Pacific Market Revenue, By Product, 2016 – 2028
      • 6.4.10.2. Rest of Asia Pacific Market Revenue, By Distribution Channel, 2016 – 2028
  • 6.5. Latin America
    • 6.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 6.5.2. Latin America Market Revenue, By Product, 2016 – 2028
    • 6.5.3. Latin America Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.5.5. Brazil
      • 6.5.5.1. Brazil Market Revenue, By Product, 2016 – 2028
      • 6.5.5.2. Brazil Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.5.6. Argentina
      • 6.5.6.1. Argentina Market Revenue, By Product, 2016 – 2028
      • 6.5.6.2. Argentina Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.5.7. Rest of Latin America
      • 6.5.7.1. Rest of Latin America Market Revenue, By Product, 2016 – 2028
      • 6.5.7.2. Rest of Latin America Market Revenue, By Distribution Channel, 2016 – 2028
  • 6.6. The Middle-East and Africa
    • 6.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Million)
    • 6.6.2. The Middle-East and Africa Market Revenue, By Product, 2016 – 2028
    • 6.6.3. The Middle-East and Africa Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.6.5. GCC Countries
      • 6.6.5.1. GCC Countries Market Revenue, By Product, 2016 – 2028
      • 6.6.5.2. GCC Countries Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.6.6. South Africa
      • 6.6.6.1. South Africa Market Revenue, By Product, 2016 – 2028
      • 6.6.6.2. South Africa Market Revenue, By Distribution Channel, 2016 – 2028
    • 6.6.7. Rest of Middle-East Africa
      • 6.6.7.1. Rest of Middle-East Africa Market Revenue, By Product, 2016 – 2028
      • 6.6.7.2. Rest of Middle-East Africa Market Revenue, By Distribution Channel, 2016 – 2028
• Chapter No. 7: Myocardial Infarction Treatment Market – Industry Analysis
  • 7.1. Introduction
  • 7.2. Market Drivers
    • 7.2.1. Driving Factor 1 Analysis
    • 7.2.2. Driving Factor 2 Analysis
  • 7.3. Market Restraints
    • 7.3.1. Restraining Factor Analysis
  • 7.4. Market Opportunities
    • 7.4.1. Market Opportunity Analysis
  • 7.5. Porter’s Five Forces Analysis
  • 7.6. PEST Analysis
  • 7.7. Regulatory Landscape
  • 7.8. By Distribution Channel Landscape
  • 7.9. Regional Market Trends
    • 7.9.1. North America
    • 7.9.2. Europe
    • 7.9.3. Asia Pacific
    • 7.9.4. Latin America
    • 7.9.5. The Middle-East and Africa
  • 7.10. Pricing Analysis
  • 7.11. Value Chain Analysis
  • 7.12. Downstream Buyers
  • 7.13. Distributors/Traders List
• Chapter No. 8: Competitive Landscape
  • 8.1. Company Market Share Analysis – 2019
    • 8.1.1. Global Myocardial Infarction Treatment Market: Company Market Share, 2019
    • 8.1.2. Global Myocardial Infarction Treatment Market, Company Market Revenue, 2016 – 2019 (USD Million)
    • 8.1.3. Global Myocardial Infarction Treatment Market, Company Y-o-Y Growth, 2017 – 2019 (%)
    • 8.1.4. Global Myocardial Infarction Treatment Market: Radar Determinant Chart, 2019
  • 8.2. Strategic Developments
    • 8.2.1. Acquisitions & Mergers
    • 8.2.2. New Product Launch
    • 8.2.3. Regional Expansion
  • 8.3. Company Strategic Developments – Heat Map Analysis
• Chapter No. 9: Company Profiles
  • 9.1. Bayer
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Product Portfolio
    • 9.1.4. Financial Overview
    • 9.1.5. Operating Business Segments
    • 9.1.6. Business Performance
    • 9.1.7. Recent Developments
  • 9.2. Novartis
  • 9.3. Daiichi Sankyo Company Limited
  • 9.4. Boehringer Ingelheim GmbH
  • 9.5. Sandoz
  • 9.6. Astrazeneca
  • 9.7. Janssen Biotech, Inc.
  • 9.8. Merck & Co. Inc.
  • 9.9. Sanofi
  • 9.10. Pfizer Inc.
• Chapter No. 10: Marketing Strategy Analysis
  • 10.1. Marketing Channel
  • 10.2. Direct Marketing
  • 10.3. Indirect Marketing
  • 10.4. Marketing Channel Development Trends
  • 10.5. Economic/Pulitical Environmental Change
• Chapter No. 11: Research Methodology
  • 11.1. Research Methodology
  • 11.2. Phase I - Secondary Research
  • 11.3. Phase II - Data Modeling
    • 11.3.1. Company Share Analysis Model
    • 11.3.2. Revenue Based Modeling
  • 11.4. Phase III - Primary Research
  • 11.5. Research Limitations
    • 11.5.1. Assumptions